ONVO - Corbus Has Ties To Suspect Investors And A History Of Failed Clinical Trials For Lenabasum
In this article, we highlight what we believe are ties between Corbus Pharmaceutical Holdings (CRBP) and a group of suspect investors that were involved during the company’s IPO. In addition, we believe lenabasum has a history of negative clinical data, and we believe that lenabasum is likely to fail in the company’s pivotal trial in Scleroderma and Systemic Sclerosis (SSc) and Phase 2b trial in cystic fibrosis (CF).
Given Corbus’ high cash burn, we expect little cash to be on the balance sheet by the time the company’s key clinical trials readout in